Destructive effect of RNаse a on the SARS-CoV-2 virus (in vitro research)
- Authors: Morozov I.A.1, Godovalov A.P.1, Oborin D.A.2
-
Affiliations:
- E.A. Vagner Perm State Medical University
- Perm Regional Center for the Prevention and Control of AIDS and Infectious Diseases
- Issue: Vol 21, No 3 (2021)
- Pages: 131-134
- Section: Conference proceedings
- Published: 06.12.2021
- URL: https://journals.eco-vector.com/MAJ/article/view/76133
- DOI: https://doi.org/10.17816/MAJ76133
- ID: 76133
Cite item
Abstract
BACKGROUND: For today, the most important and discussed issue in the professional medical community is the problem of prevention and treatment of a new coronaviral infection (COVID-19). The main reason for the non-decreasing increase in morbidity and mortality is the absence of an etiotropic drug. In our study, it is proposed to use a previously available drug for the treatment of tick-borne encephalitis, ribonuclease A, obtained from the pancreas of cattle.
AIM: The aim of investigation was to study the antiviral activity of RNаse A against SARS-CoV-2 in in vitro experiments.
MATERIALS AND METHODS: The experiment used samples of 50 patients with a confirmed (by PCR) primary diagnosis of a new coronoviral infection COVID-19. The preparation for the study was served by ribonuclease A (neoFroxx GmbH, Germany) at a concentration of 0.5; 1; 5 and 10 mg/ml, incubated at 4 and 37°C, the exposure was 20 minutes, 20 hours. A set of reagents OTT-PCR-RV-SARS-CoV-2 (Syntol, Russia) was used as test systems.
RESULTS: of the current study is the revealed antiviral activity of ribonuclease A at a minmal concentration of 0.5 mg/ml during incubation from 20 minutes to 20 hours, in the temperature range of 4–37°C.
CONCLUSIONS: The data obtained in the in vitro study confirmed the ability of ribonuclease A to destroy viral RNA, which suggests the possible use of the drug both for the treatment of patients and for the treatment of environmental objects.
Full Text
About the authors
Ilya A. Morozov
E.A. Vagner Perm State Medical University
Author for correspondence.
Email: Lonny8@yandex.ru
ORCID iD: 0000-0003-4233-3711
student, Faculty of Medicine
Russian Federation, PermAnatoly P. Godovalov
E.A. Vagner Perm State Medical University
Email: agodovalov@gmail.com
MD, PhD, Leading Research Associate at Central Scientific Laboratory, Associate Professor at Microbiology and Virology Department
Russian Federation, PermDenis A. Oborin
Perm Regional Center for the Prevention and Control of AIDS and Infectious Diseases
Email: DAOborin@yandex.ru
MD, bacteriologist
Russian Federation, PermReferences
- Romanov BK. Coronavirus disease COVID-2019. Safety and Risk of Pharmacotherapy. 2020;8(1):3–8. (In Russ.) doi: 10.30895/2312-7821-2020-8-1-3-8
- Nikiforov VV, Suranova TG, Chernobrovkina TYa, et al. New coronavirus infection (COVID-19): clinical and epidemiological aspects. The Russian Archives of Internal Medicine. 2020;10(2 (52)):87–93. (In Russ.) doi: 10.20514/2226-6704-2020-10-2-87-93
- Abaturov AE, Agafonova EA, Krivusha EL, Nikulina A.A. Pathogenesis of COVID-19. Zdorov'e rebenka. 2020;15(2):133–144. (In Russ.). doi: 10.22141/2224-0551.15.2.2020.200598
- Rosenberg HF. RNase A ribonucleases and host defense: an evolving story. J Leukoc Biol. 2008;83(5):1079–1087. doi: 10.1189/jlb.1107725
- Abaturov AYe. Ribonucleases А – the most ancient components of nonspecific protection of respiratory tract. Zdorov'e rebenka. 2011;(5(32)):136–142. (In Russ.)
- Ilinskaya ON, Shah Mahmud R. Ribonucleases as antiviral agents. Molecular Biology. 2014;48(5):615–623. doi: 10.1134/S0026893314040050
- Dyer KD, Rosenberg HF. The RNase a superfamily: generation of diversity and innate host defense. Mol Divers. 2006;10(4):585–597. doi: 10.1007/s11030-006-9028-2